about
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancerThe p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinasesLovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductaseLow-molecular-weight cyclin E: the missing link between biology and clinical outcomeHow will we recruit, train, and retain physicians and scientists to conduct translational cancer research?Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligaseA phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology.Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight formsThe neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer.Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin EElafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.Role of cell cycle in mediating sensitivity to radiotherapy.Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cellsPAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness.Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer.PKCiota promotes ovarian tumor progression through deregulation of cyclin E.Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancerSequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast CancerCyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model.Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast CancerEstrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashionAltered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation.Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent mannerTargeting low molecular weight cyclin E (LMW-E) in breast cancer.MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells.Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest.AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy.Cyclin E deregulation alters the biologic properties of ovarian cancer cells.Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells.
P50
Q21092361-626FC27E-9F05-4A62-8217-551DC41543CAQ24319848-64D54034-C014-426C-9559-88D75DAAD161Q24645348-9175C827-8F42-4ED6-ABAB-9E6083FF5BA4Q24806316-30CBCA07-B9E4-49CF-BF83-B41A18A4629FQ27026431-5838DEC1-E406-4990-AC2E-E0CA694A1BADQ28215069-73E120E3-62B2-4418-8C86-FFFF40D7CF5EQ33165699-E8035527-5282-4C2B-A7C5-E921949DC51AQ33851230-CA55A0DC-66A6-46F2-901A-6B85C30D4220Q33899115-8A01CBA6-EF96-4D60-85D0-3F3EA911C6A1Q33920769-99D08BBD-136A-44EF-AA84-CFE1249B113CQ33925994-133B8724-45FC-49C3-820D-39635FCD6F5DQ33956803-A230DE8A-CD89-4B0F-8CFB-515E427F5D1CQ33969505-614756F9-1593-48F0-8E8A-8CF019BC4823Q34134278-EEBBE7F9-BE2E-4765-A285-098E9E698321Q34157822-7A7EEE19-F0E8-4030-BB49-43A1C7918D20Q34901237-FDCD70F9-079B-44D2-8DA1-DDD055D3816AQ35079179-C04104AB-E3BD-41D9-BC67-ADCDE6DE7FD2Q35185357-C8C6E480-3AC7-4AFC-9A71-EDFAE1005FDCQ35826593-177C5DB8-7BA2-4587-B6DA-CA4BC2FD38FEQ36187728-5FEC6013-12F6-4381-8C94-D42A9FE89F41Q36549367-123F6C7E-D40C-494D-9347-193695D528A4Q36604034-C6BE99A0-9241-4952-92DF-D493AD5C5FD2Q36869444-DB378651-4BD8-4EF2-A7F7-77DE4F20C688Q36903296-A16C48B4-03CD-48B2-BF64-EBB4EEECB824Q36917747-6140811D-B01A-4098-BA1B-A70FFC0540D8Q36918276-FDA48E0E-8FE1-446B-AD45-97F9805F8E92Q36922550-3DCA19BC-7D0D-4B11-A59F-E5F7147B5C8BQ37057171-5C49AB27-2E59-45CE-9773-6B0B2C1FA844Q37068048-EE86F125-2463-49F0-8B7D-40C96F84D755Q37160444-9B067850-E3D0-4689-BFA2-ADAA44874F03Q37172133-F1F9D669-5769-4450-B14C-D2F84D298208Q37205868-0D0BB4AA-2489-4DF0-BBE1-ADD37CE4940EQ37373562-223627EE-E6A7-4CE4-B9AC-E5E3EFEED902Q37419724-1DA3570D-D9AC-474A-9BF8-A2502D129988Q37716464-42D659DC-A2A3-4EA9-9678-0F5433929003Q38723383-FC7705AE-2F03-4613-9A47-77CE6FB7BF51Q38743594-3B226F05-3644-40F7-9139-FAAAB72BB499Q40093687-324D8373-8213-4822-A3A3-55B9DE977716Q40580984-39F18545-F480-4872-A3C8-B0F86123092EQ40602827-34BFF1D4-C879-4E63-AFD9-EEAE615D106D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Khandan Keyomarsi
@ast
Khandan Keyomarsi
@en
Khandan Keyomarsi
@es
Khandan Keyomarsi
@nl
Khandan Keyomarsi
@sl
type
label
Khandan Keyomarsi
@ast
Khandan Keyomarsi
@en
Khandan Keyomarsi
@es
Khandan Keyomarsi
@nl
Khandan Keyomarsi
@sl
prefLabel
Khandan Keyomarsi
@ast
Khandan Keyomarsi
@en
Khandan Keyomarsi
@es
Khandan Keyomarsi
@nl
Khandan Keyomarsi
@sl
P106
P31
P496
0000-0002-5440-0849